CD274 and non-small cell lung carcinoma: In some non-small cell lung cancer (NSCLC) studies, PDL-1 levels equal to or exceeding 50%, based on the so called proportional score, confer a favorable response to anti-PD1 blockade (Haslam and Prasad, 2019).